Lilly will provide up to $52 million in funding for research, making this Purdue’s largest strategic corporate collaboration
Eli Lilly and Company and Purdue University have formed a strategic collaboration to conduct life science research. The five-year agreement, where Lilly will provide up to $52 million, marks Purdue's largest strategic collaboration with a single company.
The initial research focus areas include:
In the future, the partners say, collaboration may extend to other areas to best utilize the range of expertise at the two institutions. Purdue researchers from the natural and physical sciences, engineering and veterinary medicine will collaborate with Lilly researchers.
"The biomedical revolution is upon us, but harnessing its full potential will require strong collaboration between academic research centers and industry partners," said David Ricks, Lilly's chairman, president and chief executive officer. "We look forward to expanding our relationship with Purdue as we work together to discover breakthrough solutions for patients."
Source: PRNewswire
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.